Johnson & Johnson has rebranded with a new logo and a new name for its Janssen pharmaceutical business one year after renaming its medical device business — and just weeks after spinning off its consumer health business. New Brunswick, New Jersey–based Johnson & Johnson (NYSE: JNJ) has replaced its 136-year-old logo — based on the signature of co-founder James Wood Johnson — with a “more modern logo and brighter red, keeping the iconic ampersand,” J&J CEO Joaquin Duato said today in a post on LinkedIn. The change is meant to call attention to J&J’s focus on innovative medicine and medtech, he said. The Janssen Pharmaceutical Cos. of Johnson & Johnson, meanwhile, is from now on going as Johnson & Johnson Innovative Medicine, “leading where medicine is going by developing breakthrough treatments, discovering new pathways and modalities, and expanding access so patients receive optimal care,” Duato said. Drug Discovery & Development: Johnson & Johnson pharma rebrand highlights innovation as a pillar to reinforce trust The move unites the pharma business with the Johnson & Johnson Medtech device business under a single name, he explained. “The power of a single, iconic name is tremendous,” Duato said. “Around the world, patients, doctors, nurses, and investors recognize Johnson & Johnson for our ability to deliver solutions for the toughest health challenges. Our exclusive focus in biology and medical technology allows us to innovate across the full spectrum of healthcare in ways no other company can — from cell therapy to AI-assisted robotic surgery.” Johnson & Johnson just last month completed the spinoff of its consumer health brand as a new independent company called Kenvue. Johnson & Johnson MedTech is the second-largest medtech company in the world, according to Medical Design & Outsourcing‘s latest Medtech Big 100 ranking. Janssen, meanwhile, is the world’s fourth-largest pharmaceutical company, per the Pharma 50 ranking by MDO sister publication Drug Discovery & Development. The Johnson & Johnson MedTech segment covers interventional solutions, orthopedics, surgery and vision, with brand names such as Biosense Webster, Cerenovus, DePuy Synthes, Ethicon, Acclarent and Acuvue. “The new Johnson & Johnson brand embodies our dynamic spirit while staying true to what has made J&J stand apart from others: our credo, our superpower of caring, and our relentless focus on transforming health for patients,” Johnson & Johnson EVP and Worldwide MedTech Chair Ashley McEvoy said on LinkedIn. “With the intersection of technology and biology fueling rapid innovation across our industry, this is an exciting time for Team MedTech.” Johnson & Johnson’s old logo dated back to 1887, making it one of the longest-running corporate logos in history.
On September 15 this year, on the eve of the visit of the President of the Republic of Uzbekistan Sh.M.Mirziyoyev to the United States of America, the Uzbekistan-US Business Forum was held in Washington, D.C. It was attended by the heads of key ministries and departments, industry associations, commercial banks and investment structures of the two countries, as well as heads of large US corporations engaged in the fields of ICT, engineering, agriculture, light industry, transport, banking and other areas.The speakers at the opening ceremony of the forum were Jamshid Khodjaev, Deputy Prime Minister of the Republic of Uzbekistan, Laziz Kudratov, Minister of Investment, Industry and Trade, Carolyn Lamm, Chairwoman of the Board, American-Uzbek Chamber of Commerce, Reta Jo Lewis, President and Chair of the Board of Directors, EXIM Bank of the USA, and John Mark Pommersheim, Deputy Assistant Secretary of State for Central Asia.The speeches emphasized rapid dynamics in the development of trade, economic and investment relations between our countries, which was facilitated by the political will of the leadership, as well as the constant interaction of governments and business circles.The Uzbek side presented key achievements in the development of the economy, trade, industry and improvement of the investment climate. In particular, along with other facts, the created mechanisms of free market and healthy competition, active support for entrepreneurship, infrastructural development, availability of energy resources, reduction of state participation in the economy and the launch of large-scale privatization processes were noted.Thanks to the reforms carried out, Uzbekistan has become an attractive investment destination, including for American business circles. Today, 300 US companies operate in Uzbekistan, which is more than twice as many as in 2017. Success stories are observed in various sectors, including automobile manufacturing - General Motors, agricultural machinery - John Deer, CNH, gas production - Air Products, agriculture – Silverleafe and others.At the same time, the most promising areas for the implementation of joint investment projects were identified, such as mining, chemical and energy industries, textile industry, agriculture, pharmaceuticals, electronics, information technology. There are great opportunities in the creation of joint ventures to manufacture products with high added value and their export to third countries.The importance of strengthenin business contacts between the two countries and readiness to provide comprehensive state support in the implementation of all joint projects and initiatives were emphasized.During the event, separate sessions were held on issues of global competition, ensuring the sustainability of supply chains, developing the business environment, stimulating innovation, strategic forecasting, privatization and financial and technical cooperation.The work of the business forum continued with "G2B" and "B2B" meetings between the heads of ministries, departments, industry associations and leading companies of Uzbekistan and the USA. The participants were able to profoundly discuss the creation of joint ventures and the conclusion of mutually beneficial trade agreements.As a result of the event, 12 documents were signed in the fields of energy, mechanical engineering, ICT, agriculture, financial, technical, scientific and technical cooperation, production of medical and pharmaceutical products.
The United States through its Agency for International Development (USAID), signed a new Memorandum of Understanding (MOU) with the Government of Uzbekistan towards expanding access to safe and quality tuberculosis and other medicines in Uzbekistan. During the first ever Uzbek-U.S. Health Forum, held in Tashkent, USAID Mission Director in Uzbekistan David Hoffman and Minister of Health Amrillo Inoyatov signed an MOU between USAID and the Center for Pharmaceutical Products Safety under the Ministry of Health to improve the quality of medicines in Uzbekistan and support the growth of the pharmaceutical industry of Uzbekistan. Director Hoffman stated that “USAID congratulates the Government of Uzbekistan for organizing the first ever Uzbek-U.S. Health Forum, opening the doors ever wider to partnerships and coordination between our two countries.” Through its Promoting the Quality of Medicines + activity implemented by U.S. Pharmacopeia, USAID works closely with national stakeholders and counterparts in Uzbekistan to sustainably strengthen the medicines quality assurance systems and improve access to quality-assured essential medical products for Uzbek citizens. Signed MOU sets the mutual understanding of both governments to continue progress towards together achieving the shared goals of improved health for all.